Liposome composition comprising culture extract of sphingomonas olei

Encapsulating Sphingomonas olei culture extract in liposomes with glycerin, hydrogenated lecithin, and cetearyl olivate improves transdermal absorption and skin regeneration efficacy, addressing the limitations of direct application and enhancing skin health.

WO2024248263A1PCT designated stage expired Publication Date: 2024-12-05HUGEL INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/022018
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2023-12-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The challenge is to enhance the transdermal absorption rate and skin regeneration efficacy of Sphingomonas olei culture extract, which is limited by the physical protective film of the human skin barrier when applied alone.

Method used

Encapsulating the Sphingomonas olei culture extract into liposomes, specifically combining it with glycerin, hydrogenated lecithin, cetearyl olivate, and sorbitanol, to form a liposome composition that efficiently delivers the extract into the skin, improving absorption and regeneration.

Benefits of technology

The liposome composition significantly enhances skin regeneration and transdermal absorption, as demonstrated by increased cell viability and skin penetration depth compared to a non-liposomal composition, with improved skin barrier repair and inflammation reduction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023022018_05122024_PF_FP_ABST
    Figure KR2023022018_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a liposome composition comprising a culture extract of Sphingomonas olei, and a cosmetic composition comprising same. In the present invention, an extract of a culture medium of Sphingomonas olei is captured in liposomes and used to efficiently deliver the culture extract of Sphingomonas olei into the skin, such that improved skin regeneration efficacy and transdermal absorption rate are exhibited.
Need to check novelty before this filing date? Find Prior Art

Description

Liposome composition comprising Sphingomonas olei culture extract

[0001] The present invention relates to a liposome composition comprising a culture extract of Sphingomonas olei and a cosmetic composition comprising the same. The liposome composition according to the present invention efficiently delivers the culture extract of Sphingomonas olei into the skin by entrapping the extract of the culture solution of Sphingomonas olei into liposomes, thereby exhibiting improved skin regeneration efficacy and percutaneous absorption rate.

[0002]

[0003] The human skin surface is rich in waste products like dead skin cells, sweat, and sebum, creating a diverse population of microorganisms that inhabit the skin, forming the skin microbiome. The skin microbiome is a symbiotic mix of beneficial and harmful bacteria. Healthy skin has a higher concentration of beneficial bacteria, while those with atopic dermatitis or acne tend to have a higher concentration of harmful bacteria. Therefore, maintaining a balance of skin flora is known to help maintain healthy skin.

[0004] The skin flora that normally reside on the skin forms a barrier that prevents the invasion of other, more harmful microorganisms (pathogens) and contributes to the skin's immune system. Because beneficial skin bacteria do not cause disease or stimulate the immune system, if beneficial skin bacteria could be used in the production of medicines or cosmetics, they could be used with confidence, without side effects such as skin irritation.

[0005] When the skin is injured or infected, damage or inflammation of the skin tissue occurs. However, if the damage is mild, the skin usually heals on its own. Sphingomonas olei has been reported to be one of the skin flora that aids in skin regeneration and recovery, as well as the healing process of inflammation.

[0006] Meanwhile, liposomes are spherical vesicles composed of phospholipids. Phospholipids are a major component of biological membranes. Therefore, the phospholipid membrane of liposomes exhibits physiological functions and properties similar to those of biological membranes. Therefore, liposomes are used as effective drug delivery vehicles in the pharmaceutical and cosmetics industries due to their skin-friendliness and excellent safety.

[0007] Sphingomonas olei has the effect of improving skin condition, such as skin regeneration, moisturizing, and anti-inflammation. However, in the case of Sphingomonas olei culture extract, there is a problem that its application is not easy because there is a limit to absorption into the skin due to the physical protective film of the human skin barrier when simply applied.

[0008]

[0009] Accordingly, the present invention aims to provide a liposome composition having improved percutaneous absorption rate and skin regeneration efficacy by efficiently delivering a culture extract of Sphingomonas olei into the skin by encapsulating the culture extract of Sphingomonas olei into liposomes.

[0010] In addition, the present invention seeks to provide a cosmetic composition comprising the liposome composition.

[0011]

[0012] One aspect of the present invention provides a liposome composition comprising 60 to 94 vol% of a culture extract of Sphingomonas olei, 5 to 30 vol% of glycerin, 0.05 to 10 vol% of hydrogenated lecithin, 0.005 to 5 vol% of cetearyl olivate, and 0.005 to 5 vol% of sorbitan olivate.

[0013] In the present invention, Sphingomonas olei may be a viable bacterium (living bacterium) or a dead bacterium (dead bacterium). More specifically, the dead bacterium may be a bacterium killed by heat treatment.

[0014] In one specific example, Sphingomonas olei may be Sphingomonas olei CBN003 strain (accession number KACC 81169BP).

[0015] As used herein, the term "culture solution" may refer to the entire medium containing the microorganism, its metabolites, and extra nutrients obtained by culturing Sphingomonas olei for a certain period of time in a medium that can supply nutrients so that Sphingomonas olei can grow and survive in a culture device such as a test tube or a fermenter. In addition, the culture solution may refer to a culture solution obtained by removing the microorganisms from a culture solution obtained by culturing the microorganisms. Meanwhile, the liquid from the culture solution from which the microorganisms have been removed is also called a "supernatant", and may be obtained by allowing the culture solution to stand still for a certain period of time and taking only the liquid in the upper layer excluding the portion that has settled to the lower layer, removing the microorganisms through filtration, or centrifuging the culture solution to remove the sediment at the bottom and taking only the liquid in the upper layer. The "microorganisms" above refer to the microorganisms themselves of the present invention, and include the microorganisms themselves selected by separating from a skin sample or the like, or the microorganisms isolated from the culture solution by culturing the microorganisms. The above-mentioned fungi can be obtained by centrifuging the culture solution and taking the portion that has settled to the lower layer, or by allowing the fungi to settle to the lower layer of the culture solution by gravity and then removing the upper liquid after leaving it still for a certain period of time.

[0016] According to one embodiment, the culture of Sphingomonas olei of the present invention can use a medium easily selected by a person skilled in the art according to the purpose among the media used for microbial culture, and specifically, a medium used for culturing Sphingomonas, such as RCM (Reinforced Clostridium Medium), TSB (Tryptic soy broth), or BHI (Brain Heart Infusion) medium, can be used, but is not limited thereto. According to one specific example, the culture of Sphingomonas olei of the present invention can be produced by inoculating Sphingomonas olei into the microbial culture medium and using a microbial culture method known in the art (for example, static culture, etc.).

[0017] The above culture solution may include the culture solution itself, a concentrate thereof, or a lyophilized product obtained by culturing a microorganism, or a culture supernatant obtained by removing a microorganism from the culture solution, a concentrate thereof, or a lyophilized product thereof.

[0018] The above culture solution may be obtained by culturing Sphingomonas olei in an appropriate medium (e.g., R2A medium or TSB medium) at a temperature of 10°C to 40°C for a certain period of time, for example, 4 to 50 hours.

[0019] The microbial concentrate can be obtained by concentrating the microbial culture itself or the supernatant obtained after filtering the culture using centrifugation or a filter.

[0020] A culture medium and culture conditions for culturing Sphingomonas olei can be appropriately selected or modified by a person of ordinary skill in the art.

[0021] In this specification, the term "culture extract" may be used with the same meaning as "fermented extract." The culture extract may be obtained by removing microorganisms by centrifugation or filtration from a culture solution fermented with microorganisms. In addition, the culture extract includes a substance obtained by extraction from the culture solution or a concentrate thereof, and may include an extract, a diluted or concentrated extract, a dried product obtained by drying the extract, or a modified or purified product thereof, or a fraction obtained by fractionating the same.

[0022] The culture extract of Sphingomonas olei can be prepared according to a conventional method in the art.

[0023] The culture extract of Sphingomonas olei may have one or more skin condition improvement effects selected from the group consisting of skin barrier improvement, skin moisturization, skin immunity improvement, skin defense enhancement, skin inflammation suppression, skin soothing, and skin regeneration (see Korean Patent Publication No. 2361015).

[0024] The culture extract of Sphingomonas olei can promote the migration of keratinocytes on the damaged skin surface, thereby promoting the recovery of damaged epidermis. The culture extract of Sphingomonas olei can increase the expression of skin barrier-related factors (e.g., loricrin, a protein required for keratinogenesis). In addition, the culture extract of Sphingomonas olei can reduce the expression of inflammatory factors, such as factors related to atopy and pruritus (e.g., thymic stromal lymphopoietin (TSLP)) and proinflammatory cytokines (e.g., IL-6, IL-8, or IL-1α).

[0025] According to the present invention, when a culture extract of Sphingomonas olei is formulated into a liposomal composition, skin regeneration can be promoted and percutaneous absorption can be improved compared to a non-liposomal composition.

[0026] In the present invention, the term "liposome" means a liposome in the form of a substance used to stably deliver a physiologically active ingredient and maximize the penetration effect in the pharmaceutical, cosmetic, and food fields.

[0027] In the present invention, the term "encapsulation" refers to encapsulating a delivery substance to surround it and efficiently introduce it into a living body.

[0028] The liposome composition of the present invention comprises 60 to 94 vol% of a culture extract of Sphingomonas olei, 5 to 30 vol% of glycerin, 0.05 to 10 vol% of hydrogenated lecithin, 0.005 to 5 vol% of cetearyl olivate, and 0.005 to 5 vol% of sorbitan olivate.

[0029] In one specific embodiment, the liposome composition of the present invention may comprise 65 to 90 vol% of a culture extract of Sphingomonas olei, 8 to 25 vol% of glycerin, 0.1 to 7 vol% of hydrogenated lecithin, 0.05 to 4 vol% of cetearyl olivate, and 0.05 to 4 vol% of sorbitan olivate.

[0030] In one specific embodiment, the liposome composition of the present invention may comprise 70 to 85 vol% of a culture extract of Sphingomonas olei, 13 to 25 vol% of glycerin, 0.2 to 5 vol% of hydrogenated lecithin, 0.1 to 3 vol% of cetearyl olivate, and 0.1 to 3 vol% of sorbitan olivate.

[0031] The liposome composition of the present invention may contain a culture extract of Sphingomonas olei in an amount of 60 to 94% by volume, 65 to 90% by volume, or 70 to 85% by volume.

[0032] The liposome composition of the present invention includes glycerin as a stabilizer. The liposome composition of the present invention may include glycerin in an amount of 5 to 30% by volume, 8 to 25% by volume, 13 to 25% by volume, or 15 to 25% by volume. If the content of glycerin in the present invention exceeds 30% by volume, there may be a problem of increased stickiness during the manufacture of cosmetics.

[0033] The liposome composition of the present invention may contain hydrogenated lecithin as a surfactant in an amount of 0.05 to 10% by volume, 0.1 to 7% by volume, or 0.2 to 5% by volume. Lecithin refers to a mixture of various phospholipids, and the composition of the phospholipids may vary depending on their origin. Hydrogenated lecithin can be obtained by adding hydrogen to lecithin. If hydrogenated lecithin is contained in an amount less than 0.05% by volume or more than 10% by volume, there may be problems with liposome formation.

[0034] The liposome composition of the present invention comprises cetearyl olivate and sorbitan olivate as auxiliary surfactants. Cetearyl olivate is an ester of cetearyl alcohol and a fatty acid of olive oil. Sorbitan olivate is an ester of a hexitol anhydride derived from sorbitol and a fatty acid of olive oil.

[0035] The liposome composition of the present invention may comprise sorbitan olivate in an amount of 0.005 to 5% by volume, 0.05 to 4% by volume, or 0.1 to 3% by volume. In addition, the liposome composition of the present invention may comprise cetearyl olivate in an amount of 0.005 to 5% by volume, 0.05 to 4% by volume, or 0.1 to 3% by volume.

[0036] In the present invention, cetearyl olivate and sorbitan olivate form a lipid bilayer of liposomes together with hydrogenated lecithin. In the present invention, if cetearyl olivate and sorbitan olivate are included in amounts less than 0.005% by volume, there may be problems with liposome formation, and if they are included in amounts exceeding 5% by volume, there may be problems in that the efficacy of the culture extract of Sphingomonas olei may be insufficient due to a decrease in the amount of components incorporated into the liposome due to an excess of membrane components.

[0037] The liposome composition of the present invention essentially includes a culture extract of Sphingomonas olei, glycerin, hydrogenated lecithin, cetearyl olivate, and sorbitan olivate, but may additionally include components such as a liposome stabilizer, an antioxidant, etc., as needed, within a range that does not affect the essential properties of the liposome composition.

[0038] In the liposome composition of the present invention, the particle diameter of the liposome may be 25 to 300 nm, specifically 50 to 200 nm.

[0039] In addition, in another aspect of the present invention, the present invention provides a cosmetic composition comprising the liposome composition.

[0040] The above cosmetic composition may have one or more skin condition improvement effects selected from the group consisting of skin barrier improvement, skin moisturizing, skin immunity improvement, skin defense enhancement, skin inflammation suppression, skin soothing, and skin regeneration (see Korean Patent Publication No. 2361015).

[0041] The above cosmetic composition contains the liposome composition according to the present invention in an amount of 0.1 to 20% by volume, 0.1 to 15% by volume, or 0.1 to 10% by volume. In the present invention, if the cosmetic composition contains less than 0.1% by volume of the liposome composition, the effect of the culture extract of Sphingomonas olei may be minimal, and even if it contains more than 20% by volume, it is difficult to expect that the effect of the culture extract of Sphingomonas olei will increase in proportion to the amount added, which is not economically desirable.

[0042] The cosmetic composition according to the present invention may include components commonly used in cosmetic compositions, such as a metal ion sequestering agent, an active ingredient (e.g., Sodium Hyaluronate and Tocopheryl Acetate), a preservative, a thickening agent, a fragrance, and conventional auxiliary agents, and a carrier.

[0043] In addition, the cosmetic composition according to the present invention can be manufactured in the form of a formulation commonly used in the art, such as an emulsified formulation or a solubilized formulation. Examples of emulsified formulations include nourishing toners, creams, and essences, and examples of solubilized formulations include emollient toners. In addition, the cosmetic composition of the present invention can be manufactured in the form of an adjuvant for topical or systemic application commonly used in the field of dermatology by containing a dermatologically acceptable medium or base, in addition to cosmetics.

[0044] Suitable cosmetic formulations may be, for example, solutions, gels, solid or paste anhydrous products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) or non-ionic vesicular dispersions, creams, toners, lotions, powders, ointments, sprays or concealer sticks. They may also be prepared in the form of foams or aerosol compositions further containing compressed propellants.

[0045] In addition, the cosmetic composition of the present invention may further contain adjuvants commonly used in the fields of cosmetology or dermatology, such as fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics. In addition, the above ingredients may be introduced in amounts commonly used in the field of dermatology.

[0046] In the present invention, the cosmetic composition may be formulated as, for example, a skin, lotion, body lotion, cream, essence, BB (Blemish Balm) cream, etc., but is not limited thereto.

[0047] Specific formulations of the cosmetic composition of the present invention include formulations such as skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, pressed powder, loose powder, patch, spray, etc.

[0048]

[0049] A liposome composition comprising a culture extract of Sphingomonas olei according to one aspect of the present invention exhibits improved skin regeneration efficacy and percutaneous absorption rate by efficiently delivering the culture extract of Sphingomonas olei into the skin by entrapping the culture extract of Sphingomonas olei into liposomes.

[0050]

[0051] FIG. 1 is a photograph of a liposome composition of a Sphingomonas olei culture extract according to one specific example of the present invention observed using a field emission transmission electron microscope (FE-TEM).

[0052] Figure 2 is a graph showing the results of measuring the cell viability of human keratinocytes (HaCaT) according to the concentration % (v / v) of a liposomal composition (Liposome) of a Sphingomonas olei culture extract and a non-liposomal composition (Non-liposome) of a Sphingomonas olei culture extract according to one specific example of the present invention, using a WST-1 assay. The untreated group was used as a control group, and the cell viability was expressed as a % compared to the control group.

[0053] Figure 3 is an experimental result showing the migration of human keratinocytes (HaCaT) according to the concentration % (v / v) of the liposomal composition (Liposome) of Sphingomonas olei culture extract and the non-liposomal composition (Non-liposome) of Sphingomonas olei culture extract according to one specific example of the present invention. The remaining gap due to cell migration 48 hours after sample treatment is shown compared to the scratch interval at 0 hour. (N-CNT, negative control; P-CNT, positive control; #, significant compared to the N-CNT value; *, significant compared to the non-liposomal composition sample treatment value; # p<0.005; ##, ** p<0.0005; ###, *** p<0.00005)

[0054] Figure 4 is a photograph showing the migration of human keratinocytes according to the concentration % (v / v) of a liposomal composition of a Sphingomonas olei culture extract and a non-liposomal composition of a Sphingomonas olei culture extract according to one specific example of the present invention. (N-CNT, negative control; P-CNT, positive control; SFE, non-liposomal composition of a Sphingomonas olei culture extract; L-SFE, liposomal composition of a Sphingomonas olei culture extract)

[0055] FIG. 5 is a result showing the depth of percutaneous absorption over time for a liposome composition of Sphingomonas olei culture extract and a non-liposome composition of Sphingomonas olei culture extract according to one specific example of the present invention.

[0056]

[0057] Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to exemplify the present invention, and the scope of the present invention is not limited by these examples.

[0058]

[0059] Example 1. Preparation of Sphingomonas olei culture extract

[0060] Sphingomonas olei CBN003 strain (accession number KACC 81169BP) was cultured in Tryptic soy broth (TSB) medium at 34℃ with stirring, and the strain culture and cells were collected at the final point of the division phase (Log phase) of the growth curve. The collected strain culture and cells were centrifuged at 6,000 rpm for 30 minutes and then sterilized by filtration through a 0.2 μm filter to prepare a culture extract.

[0061]

[0062] Example 2. Preparation of liposome composition of Sphingomonas olei culture extract

[0063] The Sphingomonas olei culture extract prepared in Example 1, glycerin, hydrogenated lecithin, cetearyl olivate, and sorbitan olivate were mixed in the ratios shown in Table 1 below and injected into a microfluidizer to prepare a liposome composition under conditions of 10 to 20°C and 500 to 1500 bar. The composition prepared less than one day ago was used to perform the evaluation and activity analysis described below.

[0064] Ingredients (volume%) Sphingomonas olei culture extract 78.0 Glycerin 20.0 Hydrogenated lecithin 1.0 Cetearyl olivate 0.5 Sorbitan olivate 0.5 Total 100.0

[0065]

[0066] The manufactured composition was observed using a field emission transmission electron microscope (FE-TEM) and the obtained image is shown in Fig. 1, from which it can be confirmed that the liposome particles were well formed.

[0067]

[0068] Comparative Example 1. Preparation of a non-liposomal composition of Sphingomonas olei culture extract.

[0069] As shown in Table 2 below, a non-liposomal composition was prepared by adding purified water to the Sphingomonas olei culture extract prepared in Example 1 without using any other components for forming liposomes. The composition prepared less than one day ago was used for the evaluation and activity analysis described below.

[0070] Ingredients (volume%) Sphingomonas olei culture extract 78.0 Glycerin 0 Hydrogenated lecithin 0 Cetearyl olivate 0 Sorbitan olivate 0 Distilled water 22.0 Total 100.0

[0071]

[0072] Experimental Example 1. Cytotoxicity Evaluation

[0073] The toxicity of the liposome composition of the Sphingomonas olei culture extract prepared in Example 2 to cells was confirmed using the WST-1 (Water Soluble Tetrazolium-1) assay.

[0074] Human epidermal keratinocyte cell line (HaCaT) was cultured in DMEM medium (Dubelcco's modified eagle medium) containing 10% fetal bovine serum (FBS), 100 mg / mL streptomycin, and 100 U / mL penicillin at 37°C in a 5% CO2 incubator. The cultured cell line was seeded in a 24-well plate at a density of 2 × 10 5 / After dispensing into wells, the cells were cultured for 24 hours under the same conditions, and then treated with liposomal compositions and non-liposomal compositions at concentrations of 1, 2, 5, and 10% (v / v), respectively, and further cultured for 24 hours under the same conditions. After this, WST-1 solution was added to each cell culture well, and further cultured for 1 hour under the same conditions, and then the absorbance was measured at 450 nm.

[0075] As a result, the cell viability (%) of human keratinocytes (HaCaT) compared to the control group was shown in Figure 2, using the non-treated sample group as a control group. As can be seen from the experimental results, when treated with the liposome composition prepared in Example 2, the cell viability of human keratinocytes (HaCaT) compared to the control group was more than 100%, indicating that there was no toxicity to the cells.

[0076]

[0077] Experimental Example 2. Analysis of skin regeneration efficacy activity

[0078] The skin regeneration efficacy of the liposomal composition of the Sphingomonas olei culture extract prepared in Example 2 and the non-liposomal composition of the Sphingomonas olei culture extract prepared in Comparative Example 1 was compared and analyzed.

[0079] Human keratinocyte cell line (HaCaT) was cultured in DMEM medium (Dubelcco's modified eagle medium) containing 10% fetal bovine serum (FBS), 100 mg / mL streptomycin, and 100 U / mL penicillin at 37°C in a 5% CO2 incubator. The cultured cell line was seeded at 2.5 × 10 in a 6-well plate. 6 / well and cultured under the same conditions for 24 hours for cell attachment. Subsequently, after an additional 24 hours of culture in serum-free DMEM medium, straight scratches of the same interval were made on the cell monolayer and cultured in serum-free DMEM medium containing 1, 2, 5, and 10% (v / v) of liposome composition and non-liposome composition, respectively, in a 5% CO2 incubator at 37°C. As a positive control, 1 ng / mL of EGF (Epidermal growth factor) was treated and cultured in the same manner. The scratch intervals at 0 and 48 hours after sample treatment were observed under a microscope and compared and analyzed.

[0080] Figure 3 shows the experimental results showing the migration of human keratinocytes (HaCaT) according to the concentration % (v / v) of liposomal compositions (Liposome) and non-liposomal compositions (Non-liposome) of Sphingomonas olei culture extracts. The remaining gap due to cell migration 48 hours after sample treatment is shown compared to the scratch gap at 0 h. (N-CNT, negative control; P-CNT, positive control; #, significant compared to N-CNT value; *, significant compared to non-liposomal composition sample treatment value; # p<0.005; ##, ** p<0.0005; ###, *** p<0.00005)

[0081] Figure 4 is a photograph showing the migration of human keratinocytes according to the concentration % (v / v) of liposomal compositions and non-liposomal compositions of Sphingomonas olei culture extract. (N-CNT, negative control; P-CNT, positive control; SFE, non-liposomal composition of Sphingomonas olei culture extract; L-SFE, liposomal composition of Sphingomonas olei culture extract)

[0082] As can be seen from the results, both the liposomal composition and non-liposomal composition of the Sphingomonas olei culture extract showed a decrease in the scratch interval after 48 hours of culture compared to the scratch interval at 0 hours. However, it was confirmed that the scratch interval was significantly reduced in the case of treatment with the liposomal composition than in the case of treatment with the non-liposomal composition sample. In particular, the treatment with 1% and 2% liposomal compositions was more effective in reducing the scratch interval than the positive control group. These results indicate that the liposomal composition of the Sphingomonas fermented extract has superior skin regeneration efficacy compared to the non-liposomal composition.

[0083]

[0084] Experimental Example 3. Analysis of the degree of percutaneous absorption

[0085] The degree of percutaneous absorption of the liposomal composition of the Sphingomonas olei culture extract prepared in Example 2 and the non-liposomal composition of the Sphingomonas olei culture extract prepared in Comparative Example 1 was compared and analyzed.

[0086] To measure the degree of percutaneous absorption, a fluorescent reagent (Texas Red™, excitation wavelength 562 nm / emission wavelength 582-618 nm) was mixed with the strain culture medium, and samples of liposomal compositions and non-liposomal compositions were prepared. The above samples were loaded onto Franz cell membranes (APURES), which are test skins derived from minipigs, and the absorption depths were measured using a fluorescence microscope after 0, 30, 60, and 90 minutes. The penetration depth over time was compared with the penetration depth immediately after loading (0 minutes), and the results are shown in the graph of Fig. 5.

[0087] As shown in Fig. 5, the skin penetration depth of the liposomal composition of the Sphingomonas olei culture extract measured after 30 and 60 minutes was almost the same as that of the non-liposomal composition of the Sphingomonas olei culture extract. However, after 90 minutes, the liposomal composition of the Sphingomonas olei culture extract was absorbed much more than the non-liposomal composition, and the penetration depth of the liposomal composition (19 μm) was approximately 2.6 times greater than that of the non-liposomal composition (7.17 μm). These results indicate that the transdermal absorption of the liposomal composition of the Sphingomonas olei culture extract was much improved compared to that of the non-liposomal composition.

Claims

1. A liposome composition comprising 60 to 94 volume% of a culture extract of Sphingomonas olei, 5 to 30 volume% of glycerin, 0.05 to 10 volume% of hydrogenated lecithin, 0.005 to 5 volume% of cetearyl olivate, and 0.005 to 5 volume% of sorbitan olivate.

2. A liposome composition comprising 65 to 90% by volume of a culture extract of Sphingomonas olei, 8 to 25% by volume of glycerin, 0.1 to 7% by volume of hydrogenated lecithin, 0.05 to 4% by volume of cetearyl olivate, and 0.05 to 4% by volume of sorbitan olivate according to claim 1.

3. A liposome composition comprising 70 to 85 volume% of a culture extract of Sphingomonas olei, 13 to 25 volume% of glycerin, 0.2 to 5 volume% of hydrogenated lecithin, 0.1 to 3 volume% of cetearyl olivate, and 0.1 to 3 volume% of sorbitan olivate according to claim 1.

4. A liposome composition for promoting skin regeneration and improving percutaneous absorption according to claim 1.

5. A liposome composition according to claim 1, wherein the liposome diameter size is 25 to 300 nm.

6. A cosmetic composition comprising a liposome composition according to any one of claims 1 to 5.

7. A cosmetic composition comprising 0.1 to 20% by volume of a liposome composition according to claim 6.

8. A cosmetic composition comprising 0.1 to 15 volume% of a liposome composition according to claim 7.

9. A cosmetic composition comprising 0.1 to 10 volume% of a liposome composition according to claim 8.

10. A cosmetic composition in the form of a skin, lotion, body lotion, cream, essence or BB (Blemish Balm) cream according to claim 6.

Citation Information

Patent Citations

  • White bacterium of genus sphingomonas

    JP1999042082A

  • Use of Sphingomonas olei to improve skin condition

    KR102361015B1

  • Method and system for providing export electronic purchase loan service

    KR102477226B1